Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avantor To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Avantor between March 5, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - December 16, 202 ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gauzy Ltd. (NASDAQ: GAUZ) between March 11, 2025 and November 13, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 6, 2026. SO WHAT: If you purchased Gauzy securities during the Class Period you may be entitled to compensation without payment of ...

PHILADELPHIA, Dec. 15, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead ...

NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of StubHub Holdings, Inc. (NYSE: STUB). Shareholders who purchased shares of STUB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/stubhub-holdings-inc-loss-submission-form/?id=180164&from=4  CLASS PERIOD: This l ...

NEW YORK, Dec. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A (ticker: WESFX), Class C (ticker: WEFCX), and/or Class I (ticker: WEIFX) shares of the Wildermuth Fund between November 1, 2020 and June 29, 2023, both dates inclusive (the “Class Period”), of the important December 29, 2025 lead plaintiff deadline. SO WHAT: If you purchased Wildermuth Fund mutual fund shares during the Class Period you may be entitled to compensation without pa ...

诉讼公告概要 - Rosen Law Firm宣布代表在2025年3月11日至2025年11月13日期间购买Gauzy Ltd (NASDAQ: GAUZ) 证券的购买者提起集体诉讼 [1] - 诉讼指控被告在整个集体诉讼期间做出虚假和/或误导性陈述和/或未能披露相关信息 [5] 诉讼核心指控 - Gauzy的三家法国子公司缺乏偿还到期债务的财务能力 [5] - 因此 极有可能启动破产程序 [5] - 因此 极有可能触发Gauzy现有高级担保债务融资的潜在违约 [5] - 基于上述情况 被告关于Gauzy业务 运营和前景的正面陈述存在重大误导和/或缺乏合理依据 [5] 律所背景信息 - Rosen Law Firm专注于证券集体诉讼和股东衍生诉讼 [4] - 该律所曾达成针对中国公司的史上最大证券集体诉讼和解 [4] - 根据ISS Securities Class Action Services数据 该律所2017年在证券集体诉讼和解数量上排名第一 [4] - 自2013年以来 该律所每年排名前四 [4] - 该律所为投资者追回数亿美元 仅在2019年就为投资者确保了超过4.38亿美元 [4]

New York, New York--(Newsfile Corp. - December 14, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important January 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs throug ...

针对Telix Pharmaceuticals的联邦证券集体诉讼 - 一家全国性证券律师事务所正在调查针对Telix Pharmaceuticals Limited的潜在索赔 并提醒投资者注意2026年1月9日的首席原告申请截止日期 [2] - 诉讼指控公司及其高管在2025年2月21日至2025年8月28日期间 做出了虚假和/或误导性陈述 和/或未能披露重大信息 违反了联邦证券法 [1][4] 被指控的虚假陈述与隐瞒内容 - 被告在有关前列腺癌治疗候选药物的进展方面存在重大虚报 [4] - 被告在Telix的供应链及合作伙伴质量方面存在重大虚报 [4] - 因此 被告关于公司业务 运营和前景的陈述在所有相关时间都存在重大虚假和误导性 和/或缺乏合理依据 [4] 导致股价下跌的两次负面披露事件 - 2025年7月22日 公司披露收到美国证券交易委员会的传票 主要要求提供与公司关于前列腺癌治疗候选药物开发披露相关的各种文件和信息 [5] - 根据起诉书 此消息导致Telix Pharmaceuticals的美国存托凭证价格在两个交易日内下跌超过13% [5] - 2025年8月28日 公司披露其产品TLX250-CDx的生物制品许可申请收到美国食品药品监督管理局的完整回复函 其中指出了与化学 制造和控制包相关的缺陷 [6] - 美国食品药品监督管理局还记录了对两家第三方制造和供应链合作伙伴发出的缺陷通知 在重新提交申请前需要整改 [6] - 根据起诉书 此消息导致Telix Pharmaceuticals的美国存托凭证价格在两个交易日内下跌超过21% [6]

New York, New York--(Newsfile Corp. - December 14, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.SO WHAT: If you purchased Telix securities during the Class Period you may be entitled to compensation without paymen ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gauzy To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gauzy between March 11, 2025 and November 13, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - December 14, 2025) ...